The US FDA has approved Boehringer Ingelheim’s Combivent Respimat tiotropium/albuterol inhalation spray for the treatment of COPD. The Combivent Respimat soft mist inhaler will replace the Combivent CFC-propelled MDI, which is to be phased out by December 31, 2013. The Combivent Respimat inhaler, which does not use any propellant, will be available by mid-2012.
“Boehringer Ingelheim invested more than 10 years developing Combivent Respimat. We are committed to ensuring patients and healthcare professionals are accurately instructed on how to use the new type of inhaler, before Combivent MDI is no longer on the market,” commented Boehringer Ingelheim Senior Vice President, Medicine and Regulatory, Christopher Corsico.
Read the FDA announcement.
Read the Boehringer Ingelheim press release.
